title: Emerging antibody-based products.
abstract: Antibody-based products are not widely available to address many global health challenges due to high costs, limited manufacturing capacity, and long manufacturing lead times. There are now tremendous opportunities to address these industrialization challenges as a result of revolutionary advances in plant virus-based transient expression. This review focuses on some antibody-based products that are in preclinical and clinical development, and have scaled up manufacturing and purification (mg of purified mAb/kg of biomass). Plant virus-based antibody products provide lower upfront cost, shorter time to clinical and market supply, and lower cost of goods (COGs). Further, some plant virus-based mAbs may provide improvements in pharmacokinetics, safety and efficacy.
authors: Mapp Biopharmaceutical Inc, 6160 Lusk Blvd, Suite C105, San Diego, CA, 92121, USA, Kevin.whaley@mappbio.com.
authors: Kevin J
authors: KJ
authors: Whaley
authors: Josh
authors: J
authors: Morton
authors: Steve
authors: S
authors: Hume
authors: Ernie
authors: E
authors: Hiatt
authors: Barry
authors: B
authors: Bratcher
authors: Victor
authors: V
authors: Klimyuk
authors: Andrew
authors: A
authors: Hiatt
authors: Michael
authors: M
authors: Pauly
authors: Larry
authors: L
authors: Zeitlin
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000235:genetics* / Q000627:therapeutic use; D046129:Ebola Vaccines / Q000627:therapeutic use; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000627:therapeutic use; D010942:Plant Viruses / Q000235:genetics*
chemical_list: D000911:Antibodies, Monoclonal; D046129:Ebola Vaccines; D007130:Immunoglobulin Idiotypes